Anivive Lifesciences Announces FDA Approval of Laverdia®, the First Oral Treatment of Its Kind for Canine Lymphoma

Anivive converts Laverdia-CA1 to full FDA approval First FDA-approved product to validate Anivive's AI-enabled development model — from drug repurposing through clinical trial enrollment Affordable oral lymphoma treatment administered at home Additional approvals underway in Australia,...